|
Impact of the 21-gene Recurrence Score assay on the adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes in an academic centre in Ontario. |
|
|
Research Funding - Genomic Health (Inst) |
|
|
Stock and Other Ownership Interests - RNA Diagnostics |
|
Consulting or Advisory Role - Nanostring/Innomar Strategies; RNA Diagnostics |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Eisai (Inst); Novartis (Inst); Pfizer (Inst); Roche Canada (Inst) |
Other Relationship - AstraZeneca; Eisai; Novartis; Roche Canada |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Merck; Novartis; Pfizer; Roche/Genentech |
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; Lilly; Novartis; Roche/Genentech |
|
|
Honoraria - Amgen; AstraZeneca; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche |
|
|
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche |
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Genomic Health (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |